litlas
Log inCreate account

Henrik Schmidt

Active 1981–2026

Also published as
henrik Schmidt
140
Papers
26,956
Citations
58
h-index
123
i10-index

Citations

Citations per year for Henrik Schmidt1984: 1 citations1985: 1 citations1986: 1 citations1987: 1 citations1989: 4 citations1990: 1 citations1991: 4 citations1992: 4 citations1993: 14 citations1994: 7 citations1995: 5 citations1996: 14 citations1997: 8 citations1998: 18 citations1999: 11 citations2000: 18 citations2001: 13 citations2002: 14 citations2003: 12 citations2004: 15 citations2005: 16 citations2006: 25 citations2007: 21 citations2008: 17 citations2009: 33 citations2010: 57 citations2011: 59 citations2012: 92 citations2013: 133 citations2014: 115 citations2015: 234 citations2016: 383 citations2017: 454 citations2018: 421 citations2019: 1,014 citations2020: 1,195 citations2021: 1,192 citations2022: 1,006 citations2023: 753 citations2024: 1,190 citations2025: 642 citations2026: 32 citations1988: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,189 citing papers, 24.1% of this breakdownChina: 1,548 citing papers, 11.7% of this breakdownUnited Kingdom: 761 citing papers, 5.8% of this breakdownGermany: 755 citing papers, 5.7% of this breakdownFrance: 716 citing papers, 5.4% of this breakdownItaly: 708 citing papers, 5.3% of this breakdownAustralia: 524 citing papers, 4% of this breakdownNetherlands: 456 citing papers, 3.4% of this breakdownJapan: 440 citing papers, 3.3% of this breakdownCanada: 386 citing papers, 2.9% of this breakdownSpain: 369 citing papers, 2.8% of this breakdownSwitzerland: 335 citing papers, 2.5% of this breakdown
0%24.1%Other 23.1%

Institutions

Fields

  • Medicine59.2%
  • Biochemistry, Genetics and Molecular Biology11.4%
  • Immunology and Microbiology11%
  • Engineering9.5%
  • Earth and Planetary Sciences3.8%
  • Computer Science2.1%
  • Other3%

Topics

  • Cancer Immunotherapy and Biomarkers17.1%
  • Immunotherapy and Immune Responses8%
  • CAR-T cell therapy research5.9%
  • Immune Cell Function and Interaction3.7%
  • Cutaneous Melanoma Detection and Management3.5%
  • Melanoma and MAPK Pathways3.4%
  • Other58.4%

Coauthors

All papers

Open in search
  1. Tertiary lymphoid structures improve immunotherapy and survival in melanoma

    Authors: Rita Cabrita, Martin Lauss, Adriana Sanna, Marco Donia, Mathilde Skaarup Larsen, Shamik Mitra, Iva Johansson, Bengt Phung, Katja Harbst, Johan Vallon‐Christersson, Alison van Schoiack, Kristina Lövgren, Sarah Warren, Karin Jirström, Håkan Olsson, Kristian Pietras, Christian Ingvar, Karolin Isaksson, Dirk Schadendorf, Henrik Schmidt, Lars Bastholt, Ana Carneiro, Jennifer A. Wargo, Inge Marie Svane, Göran Jönsson - Nature 2020 cited by 2,413

  2. Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    Authors: Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Ana Arance, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, L. Lundgren-Eriksson, Christine E. Horak, Brian J. Sharkey, Ian M. Waxman, Victoria Atkinson, Paolo A. Ascierto - New England Journal of Medicine 2014 cited by 5,352

  3. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock

    Authors: Jacob Eifer Møller, Thomas Engstrøm, Lisette Okkels Jensen, Hans Eiskjær, Norman Mangner, Amin Polzin, P. Christian Schulze, Carsten Skurk, Peter Nordbeck, Peter Clemmensen, Vasileios Panoulas, Sebastian Zimmer, Andreas Schäfer, Nikos Werner, Martin Frydland, Lene Holmvang, Jesper Kjærgaard, Rikke Sørensen, Jacob Lønborg, Matias Greve Lindholm, Nanna Louise Junker Udesen, Anders Junker, Henrik Schmidt, Christian Juhl Terkelsen, Steffen Christensen, Evald Høj Christiansen, Axel Linke, Felix Woitek, Ralf Westenfeld, Sven Möbius‐Winkler, Kristian Wachtell, Hanne Berg Ravn, Jens Flensted Lassen, Søren Boesgaard, Oke Gerke, Christian Hassager - New England Journal of Medicine 2024 cited by 826

  4. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  5. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Authors: Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Lars Bastholt, Laurent Mortier, L. Thomas, Saad Tahir, Axel Hauschild, Jessica C. Hassel, F. Stephen Hodi, Corina Taitt, Veerle de Pril, Gaetan de Schaetzen, Stefan Suciu, Alessandro Testori - New England Journal of Medicine 2016 cited by 1,313

  6. Phenotyping Cardiogenic Shock

    Authors: Elric Zweck, Katherine Thayer, Ole Kristian Lerche Helgestad, Manreet Kanwar, Mohyee Ayouty, A.R. Garan, Jaime Hernández-Montfort, Claudius Mahr, Detlef Wencker, Shashank S. Sinha, Esther Vorovich, Jacob Abraham, William W. O’Neill, Song Li, Gavin Hickey, Jakob Josiassen, Christian Hassager, Lisette Okkels Jensen, Lene Holmvang, Henrik Schmidt, Hanne Berg Ravn, Jacob Eifer Møller, Daniel Burkhoff, Navin K. Kapur - Journal of the American Heart Association 2021 cited by 251

  7. Computational Ocean Acoustics

    Authors: Finn B. Jensen, W. A. Kuperman, Michael B. Porter, Henrik Schmidt - Modern acoustics and signal processing 2011 cited by 1,589

  8. The wound inflammatory response exacerbates growth of pre‐neoplastic cells and progression to cancer

    Authors: Nicole Antonio, Marie Louise Bønnelykke‐Behrndtz, Laura Ward, J. Collin, Ib Jarle Christensen, Torben Steiniche, Henrik Schmidt, Yi Feng, Paul Martin - The EMBO Journal 2015 cited by 282

  9. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

    Authors: Neil H. Segal, Theodore F. Logan, F. Stephen Hodi, David F. McDermott, Ignacio Melero, Omid Hamid, Henrik Schmidt, Caroline Robert, Vanna Chiarion‐Sileni, Paolo A. Ascierto, Michele Maio, Walter J. Urba, Tara C. Gangadhar, Satyendra Suryawanshi, Jaclyn Neely, Maria Jure–Kunkel, Suba Krishnan, Holbrook E. Kohrt, Mario Sznol, Ronald Levy - Clinical Cancer Research 2016 cited by 412

  10. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Authors: Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Axel Hoos, Veerle de Pril, Ravichandra Karra Gurunath, Gaetan de Schaetzen, Stefan Suciu, Alessandro Testori - The Lancet Oncology 2015 cited by 1,255

  11. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Authors: Sandra P. D’Angelo, James Larkin, Jeffrey A. Sosman, Célèste Lebbé, Benjamin Brady, Bart Neyns, Henrik Schmidt, Jessica C. Hassel, F. Stephen Hodi, Paul Lorigan, Kerry J. Savage, Wilson H. Miller, Peter Mohr, Iván Márquez‐Rodas, J. Charles, Martin Kaatz, Mario Sznol, Jeffrey S. Weber, Alexander N. Shoushtari, Mary Ruisi, Joel Jiang, Jedd D. Wolchok - Journal of Clinical Oncology 2017 cited by 643

  12. Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest

    Authors: Jesper Kjærgaard, Jacob Eifer Møller, Henrik Schmidt, Johannes Grand, Simon Mølstrøm, Britt Borregaard, Søren Venø, Laura Sarkisian, Dmitry Mamaev, Lisette Okkels Jensen, Benjamin Nyholm, Dan Eik Høfsten, Jakob Josiassen, Jakob Hartvig Thomsen, Jens Jakob Thune, Laust Emil Roelsgaard Obling, Matias Greve Lindholm, Martin Frydland, M Meyer, Matilde Winther‐Jensen, Rasmus Paulin Beske, Ruth Frikke‐Schmidt, Sebastian Wiberg, Søren Boesgaard, Søren Aalbæk Madsen, Vibeke Lind Jørgensen, Christian Hassager - New England Journal of Medicine 2022 cited by 263

  13. Oxygen Targets in Comatose Survivors of Cardiac Arrest

    Authors: Henrik Schmidt, Jesper Kjærgaard, Christian Hassager, Simon Mølstrøm, Johannes Grand, Britt Borregaard, Laust Emil Roelsgaard Obling, Søren Venø, Laura Sarkisian, Dmitry Mamaev, Lisette Okkels Jensen, Benjamin Nyholm, Dan Eik Høfsten, Jakob Josiassen, Jakob Hartvig Thomsen, Jens Jakob Thune, Matias Greve Lindholm, M Meyer, Matilde Winther‐Jensen, Marc Sørensen, Martin Frydland, Rasmus Paulin Beske, Ruth Frikke‐Schmidt, Sebastian Wiberg, Søren Boesgaard, Vibeke Lind Jørgensen, Jacob Eifer Møller - New England Journal of Medicine 2022 cited by 247

  14. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

    Authors: Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Anna Maria Di Giacomo, Laurent Mortier, Piotr Rutkowski, Jessica C. Hassel, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Célèste Lebbé, J. Charles, Micaela Hernberg, Kerry J. Savage, Vanna Chiarion‐Sileni, Catalin Mihalcioiu, Cornelia Mauch, Ana Arance, Francesco Cognetti, Lars Ny, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, Jesús Zoco, Sandra Re, Paolo A. Ascierto, Victoria Atkinson - Journal of Clinical Oncology 2020 cited by 227

  15. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

    Authors: Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Rosalie Stephens, Inge Marie Svane, Michal Lotem, Mahmoud Abu-Amna, Eduard Gasal, Razi Ghori, Scott J. Diede, Elizabeth Croydon, Antoni Ribas, Paolo A. Ascierto - Journal for ImmunoTherapy of Cancer 2020 cited by 173

  16. Temporal Trends in Incidence and Patient Characteristics in Cardiogenic Shock Following Acute Myocardial Infarction from 2010 to 2017: A Danish Cohort Study

    Authors: Ole Kristian Lerche Helgestad, Jakob Josiassen, Christian Hassager, Lisette Okkels Jensen, Lene Holmvang, Anne Lykke Sørensen, Martin Frydland, Annmarie Touborg Lassen, Nanna Louise Junker Udesen, Henrik Schmidt, Hanne Berg Ravn, Jacob Eifer Møller - European Journal of Heart Failure 2019 cited by 175

  17. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Authors: Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar‐Sela, Félix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas - Nature Medicine 2019 cited by 323

  18. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

    Authors: Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Fareeda Hosein, Veerle de Pril, Michal Kiciński, Stefan Suciu, Alessandro Testori - European Journal of Cancer 2019 cited by 180

  19. An immune-active tumor microenvironment favors clinical response to ipilimumab

    Authors: Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang, Omid Hamid, Henrik Schmidt, John Cogswell, Suresh Alaparthy, David M. Berman, Maria Jure–Kunkel, Nathan O. Siemers, Jeffrey R. Jackson, Vafa Shahabi - Cancer Immunology Immunotherapy 2011 cited by 777

  20. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma

    Authors: Trine Øllegaard Jensen, Henrik Schmidt, Holger Jon Møller, Frede Donskov, Morten Høyer, Pia Sjoegren, Ib Jarle Christensen, Torben Steiniche - Cancer 2011 cited by 280

  21. Duration of Device-Based Fever Prevention after Cardiac Arrest

    Authors: Christian Hassager, Henrik Schmidt, Jacob Eifer Møller, Johannes Grand, Simon Mølstrøm, Rasmus Paulin Beske, Søren Boesgaard, Britt Borregaard, Ditte Bekker‐Jensen, Jordi S. Dahl, Martin Frydland, Dan Eik Høfsten, Y Abdi Isse, Jakob Josiassen, Vibeke R. L. Jørgensen, Daniel Kondziella, Matias Greve Lindholm, Emil Moser, Benjamin Nyholm, Laust Emil Roelsgaard Obling, Laura Sarkisian, Frederik T. Søndergaard, Jakob Hartvig Thomsen, Jens Jakob Thune, Søren Venø, Sebastian Wiberg, Matilde Winther‐Jensen, M Meyer, Jesper Kjærgaard - New England Journal of Medicine 2022 cited by 94

  22. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

    Authors: Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M. Hyams, Henry Gómez, Lars Bastholt, Scott D. Chasalow, David M. Berman - Journal of Translational Medicine 2011 cited by 531

  23. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

    Authors: Yanina Jansen, Elisa A. Rozeman, Robert M. Mason, Simone M. Goldinger, Marnix H. Geukes Foppen, Lise Hoejberg, Henrik Schmidt, Johannes V. van Thienen, John B.A.G. Haanen, Leena Tiainen, Inge Marie Svane, Siru Mäkelä, Teofila Seremet, Ana Arance, Reinhard Dummer, Lars Bastholt, Marta Nyakas, Oddbjørn Straume, Alexander M. Menzies, Georgina V. Long, Victoria Atkinson, Christian U. Blank, Bart Neyns - Annals of Oncology 2019 cited by 228

  24. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial

    Authors: Nanna Junker Udesen, Jacob Eifer Møller, Matias Greve Lindholm, Hans Eiskjær, Andreas Schäfer, Nikos Werner, Lene Holmvang, Christian Juhl Terkelsen, Lisette Okkels Jensen, Anders Junker, Henrik Schmidt, Kristian Wachtell, Hölger Thiele, Thomas Engstrøm, Christian Hassager - American Heart Journal 2019 cited by 203